Establishment of new molecular-targeted therapy for leukemia mediated through HIF-1 regulation by ROS
ROS介导的HIF-1调控白血病新分子靶向治疗的建立
基本信息
- 批准号:17591010
- 负责人:
- 金额:$ 2.24万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2005
- 资助国家:日本
- 起止时间:2005 至 2006
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The therapeutic approach to leukemia is based on chemotherapy, but the side effects of the drugs used and various complications are sometimes fatal. Recently, molecular-targeted therapy is pay attention in the clinical setting ; therefore, we have sought out new agents to establish the more non-invasive therapy for the patients with leukemiaWe have reported that reactive oxygen species (ROS) are key mediators of apoptosis induced by a green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG). EGCG rapidly induced apoptosis in MPO-positive, but not MPO-negative leukemia cell lines as well as fresh samples from AML. Pre-incubation of MPO-positive leukemic cells with the MPO-specific inhibitor, 4-aminobenzoic acid hydrazide (ABAH), and the heme biosynthesis inhibitor, succinylacetone (ScAc), resulted in inhibition of the ROS production and induction of apoptosis following addition of EGCG. To investigate the role of MPO in EGCG-induced apoptosis, we transfected the full length MPO cDNA … More and empty vector into MPO-negative K562 cells. In contrast to control cells, MPO transfected cells enhanced MPO activity and ROS production, and sensitized EGCG-resistant K562 cells to apoptosis induced by ROS-producing agents. In addition, an enzymatically inactive MPO mutant expressing K562 (K562/H502A) cells could not respond to EGCG, suggesting that MPO is important for determining the sensitivity to EGCG-induced oxidative stress. Further, it is noteworthy that the fluorescence intensity of both APF-and HPF-loaded myeloid leukemic cells significantly increased upon stimulation with EGCG suggesting that EGCG generated highly toxic ROS in MPO-positive leukemic cells. Taken together, these observations indicate that highly toxic ROS such as hydroxyl radical generated via the H_2O_2/MPO/halide system induce apoptosis, and that such ROS may be the direct mediators of oxidative stress-induced apoptosis in MPO-positive leukemic cells. Gene expression profiling with Affimetrix gene chips demonstrated HIF-1α and its down-stream genes (RTP801,EGR-1,BNIP3, and VEGF), that were up-regulated, suggesting that HIF-1α pathways will be important for ROS-mediated apoptosis. Less
白血病的治疗方法是以化疗为基础的,但所用药物的副作用和各种并发症有时是致命的。近年来,分子靶向治疗在临床上受到重视,因此,我们寻找新的药物来建立更无创的治疗白血病患者的方法。据报道,活性氧(ROS)是绿茶多酚(-)-表没食子儿茶素没食子酸酯(EGCG)诱导细胞凋亡的关键介质。EGCG能迅速诱导MPO阳性、MPO阴性白血病细胞株和AML新鲜标本的凋亡。用MPO特异性抑制剂4-氨基苯甲酸肼(ABAH)和血红素生物合成抑制剂琥珀酰丙酮(SCAC)预先孵育MPO阳性的白血病细胞,可抑制加入EGCG后ROS的产生,并诱导细胞凋亡。为了研究MPO在EGCG诱导的细胞凋亡中的作用,我们将全长的MPO基因…更多空载体入MPO阴性的K562细胞。与对照组相比,MPO转染组细胞MPO活性增强,ROS生成增加,并使耐EGCG的K562细胞对ROS产生剂诱导的细胞凋亡敏感。此外,表达K562(K562/H502a)细胞的MPO突变体对EGCG没有反应,这表明MPO在决定对EGCG诱导的氧化应激的敏感性方面起着重要作用。此外,值得注意的是,在EGCG刺激下,APF和HPF负载的髓系白血病细胞的荧光强度都显著增加,这表明EGCG在MPO阳性的白血病细胞中产生了高度毒性的ROS。综上所述,这些观察结果表明,通过H_2O_2/MPO/卤化物系统产生的高毒性ROS(如羟基自由基)可诱导细胞凋亡,这种ROS可能是氧化应激诱导MPO阳性白血病细胞凋亡的直接介质。用Affimetrix基因芯片进行基因表达谱分析发现,HIF-1α及其下游基因(RTP801、EGR-1、BNIP3和血管内皮生长因子)表达上调,提示HIF-1α通路在ROS介导的细胞凋亡中具有重要作用。较少
项目成果
期刊论文数量(51)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor.
设计的 ATRA 类似物对 ATRA 耐药性急性早幼粒细胞白血病细胞具有活性,其视黄酸受体中具有单核苷酸取代。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:N.Komura;K.Umezawa;et al.
- 通讯作者:et al.
Resvexatrol induces apoptosis of human malignant B cells by activation of caspase-3 and MAP kinase pathways.
Resvexatrol 通过激活 caspase-3 和 MAP 激酶途径诱导人类恶性 B 细胞凋亡。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Shimizu T;et al.
- 通讯作者:et al.
Establishment of a new human acute monocytic leukemia cell line TZ-1 with t(1;11)(p32;g23) and fusion gene MLL-EPS15.
建立带有t(1;11)(p32;g23)和融合基因MLL-EPS15的新人急性单核细胞白血病细胞系TZ-1。
- DOI:
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Sagawa M;et al.
- 通讯作者:et al.
p27KIP1 and GATA-1 are potential downstream molecules in activin A-induced differentiation and apoptosis pathways in CML cells.
- DOI:10.3892/or.16.5.1099
- 发表时间:2006-11
- 期刊:
- 影响因子:4.2
- 作者:Y. Fukuchi;K. Yamato;Chiharu Kawamura;Y. Ikeda;M. Kizaki
- 通讯作者:Y. Fukuchi;K. Yamato;Chiharu Kawamura;Y. Ikeda;M. Kizaki
Tubulin-polymerization inhibitors derived from thalidomide
- DOI:10.1016/j.bmcl.2004.10.072
- 发表时间:2005-01-17
- 期刊:
- 影响因子:2.7
- 作者:Inatsuki, S;Noguchi, T;Kobayashi, H
- 通讯作者:Kobayashi, H
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIZAKI Masahiro其他文献
KIZAKI Masahiro的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIZAKI Masahiro', 18)}}的其他基金
Development of new therapeutic approach for multiple myeloma targeted against biological properties of bone marrow microenvironment
针对骨髓微环境的生物学特性开发多发性骨髓瘤新治疗方法
- 批准号:
24591409 - 财政年份:2012
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of novel molecular-targeting therapy for multiple myeloma against its progenitor cells
开发针对多发性骨髓瘤祖细胞的新型分子靶向疗法
- 批准号:
21591219 - 财政年份:2009
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regulation of human leukemic stem cell by reactive oxygen species (ROS) and its therapeutic applications in the clinics
活性氧(ROS)对人白血病干细胞的调控及其临床治疗应用
- 批准号:
19591137 - 财政年份:2007
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of novel differentiation-inducing therapy for leukemia with hematopoietic growth factors and arsenic trioxide
造血生长因子和三氧化二砷新型白血病诱导分化疗法的建立
- 批准号:
13671083 - 财政年份:2001
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of apoptosis and differentiation induced by arsenic trioxide in leukemic cells and its clinical application
三氧化二砷诱导白血病细胞凋亡和分化的机制及其临床应用
- 批准号:
11671015 - 财政年份:1999
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of leukemic cell differentiation and apoptosis by retinoids.
类视黄醇白血病细胞分化和凋亡的分子机制。
- 批准号:
08671257 - 财政年份:1996
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of retinoic acid receptor in normal and leukemic bone marrow stromal cells
视黄酸受体在正常和白血病骨髓基质细胞中的作用
- 批准号:
05670929 - 财政年份:1993
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似海外基金
Molecular target and circuitry underlying the preclinical effects of psychedelics in models of opioid use disorder
阿片类药物使用障碍模型中迷幻药临床前作用的分子靶点和电路
- 批准号:
10751173 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
ATIC is a novel molecular target in diffuse intrinsic pontine glioma
ATIC是弥漫性内源性脑桥胶质瘤的新型分子靶点
- 批准号:
10712984 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
A New Molecular Target to Enhance Poststroke Cognitive Recovery
增强中风后认知恢复的新分子靶点
- 批准号:
10658539 - 财政年份:2023
- 资助金额:
$ 2.24万 - 项目类别:
Tissue Engineering of 3D bone marrow niche for hematopoietic stem cells vs acute myeloid leukemia stem cell molecular target and therapeutics discovery
造血干细胞 3D 骨髓生态位的组织工程与急性髓系白血病干细胞分子靶标和治疗发现
- 批准号:
468535 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Operating Grants
Identifying the molecular target for macrophage activation by chlorpyrifos
确定毒死蜱激活巨噬细胞的分子靶标
- 批准号:
10555298 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
PLAG1 and HMGA2 Gene Rearrangements in Salivary duct Carcinoma - Preclinical Study of Novel Molecular Target Therapy -.
唾液腺管癌中的 PLAG1 和 HMGA2 基因重排 - 新型分子靶向治疗的临床前研究 -。
- 批准号:
22K09938 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identifying the molecular target for macrophage activation by chlorpyrifos
确定毒死蜱激活巨噬细胞的分子靶标
- 批准号:
10467360 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Drug Discovery Targeting Mitochondrial Iron Sulfur Protein MiNT, a Novel Molecular Target for Anti-Mitochondrial Therapy
靶向线粒体铁硫蛋白 MiNT 的药物发现,一种抗线粒体治疗的新分子靶点
- 批准号:
22K19383 - 财政年份:2022
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
New strategy of diagnostic imaging probes prior to administrating molecular target drugs
分子靶向药物给药前诊断成像探针的新策略
- 批准号:
20K16722 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular target testing in a preclinical culture assay of Emery Dreifuss muscular dystrophy
Emery Dreifuss 肌营养不良症临床前培养测定中的分子靶点测试
- 批准号:
466912 - 财政年份:2021
- 资助金额:
$ 2.24万 - 项目类别:
Studentship Programs














{{item.name}}会员




